97-7549. Oral Dosage Form New Animal Drugs; Lufenuron Tablets  

  • [Federal Register Volume 62, Number 58 (Wednesday, March 26, 1997)]
    [Rules and Regulations]
    [Page 14301]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 97-7549]
    
    
    -----------------------------------------------------------------------
    
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    21 CFR Part 520
    
    
    Oral Dosage Form New Animal Drugs; Lufenuron Tablets
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Final rule.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
    drug regulations to reflect approval of a new animal drug application 
    (NADA) filed by Ciba-Geigy Animal Health Corp. The NADA provides for 
    oral administration of lufenuron tablets to cats and kittens 6 weeks of 
    age and older for the control of flea populations.
    
    EFFECTIVE DATE: March 26, 1997.
    
    FOR FURTHER INFORMATION CONTACT: Marcia K. Larkins, Center for 
    Veterinary Medicine (HFV-112), Food and Drug Administration, 7500 
    Standish Pl., Rockville, MD 20855, 301-594-0614.
    
    SUPPLEMENTARY INFORMATION: Ciba-Geigy Animal Health Corp., P.O. Box 
    18300, Greensboro, NC 27419-8300, filed NADA 141-062, which provides 
    for oral administration of Program (Lufenuron) Cat Flavor 
    Tablets for cats and kittens 6 weeks of age or older, for the control 
    of flea populations. The drug is given orally, once a month, at a 
    minimum of 13.6 milligrams (mg) of lufenuron per pound of body weight 
    (30 mg/kilogram), in tablets containing 135 or 270 mg lufenuron each. 
    Lufenuron has no deleterious effect on adult fleas, but it prevents 
    most flea eggs from hatching or maturing into adults. The NADA is 
    approved as of March 3, 1997, and the regulations are amended in 21 CFR 
    520.1288(a) and (d) to reflect the approval. The basis of approval is 
    discussed in the freedom of information summary.
    
        In accordance with the freedom of information provisions of 21 CFR 
    part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness 
    data and information submitted to support approval of this application 
    may be seen in the Dockets Management Branch (HFA-305), Food and Drug 
    Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857, 
    between 9 a.m. and 4 p.m., Monday through Friday.
    
        Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and 
    Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for 
    3 years of marketing exclusivity beginning March 3, 1997, because the 
    NADA contains substantial evidence of effectiveness of the drug 
    involved or any studies of animal safety, required for approval and 
    conducted or sponsored by the applicant.
        The agency has determined under 21 CFR 25.24(d)(1)(iii) that this 
    action is of a type that does not individually or cumulatively have a 
    significant effect on the human environment. Therefore, neither an 
    environmental assessment nor an environmental impact statement is 
    required.
    
    List of Subjects in 21 CFR Part 520
    
        Animal drugs.
        Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
    authority delegated to the Commissioner of Food and Drugs and 
    redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is 
    amended as follows:
    
    PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS
    
        1. The authority citation for 21 CFR part 520 continues to read as 
    follows:
    
        Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act 
    (21 U.S.C. 360b).
    
        2. Section 520.1288 is amended by revising paragraphs (a), (d) (1), 
    and (d) (3) to read as follows:
    
    Sec. 520.1288  Lufenuron tablets.
    
        (a) Specifications--(1) Dogs. Each tablet contains either 45, 90, 
    204.9, or 409.8 milligrams (mg) lufenuron.
        (2) Cats. Each regular tablet contains either 90 or 204.9 mg 
    lufenuron, each flavor tablet contains 135 or 270 mg lufenuron.
    * * * * *
        (d) Conditions of use in cats--(1) Amount. Minimum of 13.6 mg 
    lufenuron per pound (lb) of body weight (30 mg per kilogram). 
    Recommended 90 mg regular tablet for cats up to 6 lb of body weight, 
    204.9 mg regular tablet for 7 to 15 lb, 135 mg flavor tablet for up to 
    10 lb, 270 mg flavor tablet for 11 to 20 lb. Cats over 15 lb (regular 
    tablet) or over 20 lb (flavor tablet) are provided the appropriate 
    combination of tablets.
    * * * * *
        (3) Limitations. For oral use in cats or kittens 6 weeks of age or 
    older, once a month, directly or broken and mixed with wet food. 
    Administer in conjunction with a full meal to ensure adequate 
    absorption. Treat all cats in the household to ensure maximum benefits. 
    Because the drug has no affect on adult fleas, the concurrent use of 
    insecticides that kill adults may be necessary depending on the 
    severity of the infestation.
    
        Dated: March 17, 1997.
    Stephen F. Sundlof,
    Director, Center for Veterinary Medicine.
    [FR Doc. 97-7549 Filed 3-25-97; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Effective Date:
3/26/1997
Published:
03/26/1997
Department:
Health and Human Services Department
Entry Type:
Rule
Action:
Final rule.
Document Number:
97-7549
Dates:
March 26, 1997.
Pages:
14301-14301 (1 pages)
PDF File:
97-7549.pdf
CFR: (1)
21 CFR 520.1288